US Stock MarketDetailed Quotes
CMPX Compass Therapeutics
- 1.010
- +0.110+12.22%
Close Aug 8 16:00 ET
- 1.050
- +0.040+3.96%
Post 17:43 ET
138.97MMarket Cap-2885P/E (TTM)
1.050High0.980Low515.64KVolume1.050Open0.900Pre Close524.62KTurnover0.58%Turnover RatioLossP/E (Static)137.59MShares2.58052wk High0.88P/B89.46MFloat Cap0.76552wk Low--Dividend TTM88.57MShs Float8.800Historical High--Div YieldTTM7.78%Amplitude0.765Historical Low1.017Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
Compass Therapeutics Stock Forum
NEWS
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Compass Therapeutics dosed the first patient in the Phase 1 trial of CTX-8371, a novel dual checkpoint blocker targeting PD-1 and PD-L1 in patients with solid tumors. The study aims to evaluate the drug's efficacy in patients who failed prior checkpoint blocker treatments.
• $Livent (LTHM.US)$ +22.58% (it posted better-than-expected quarterly earnings and raised its 2022 revenue forecast)
• $Super Micro Computer (SMCI.US)$ +11.01% (earnings reports)
• $Oatly Group AB (OTLY.US)$ +8.31% (earnings reports)
• $BlueLinx Holdings (BXC.US)$ +9.7% (increases share repurchase authorization to $100 mln; enters into $60 mln accelerated repurchase agreement)
• $Starbucks (SBUX.US)$ +7.18% (matched estimates wi...
No comment yet